Alexion Pharmaceuticals, Inc. (ALXN) Stake Boosted by Factory Mutual Insurance Co.

Alexion Pharmaceuticals, Inc. (ALXN) Stake Boosted by Factory Mutual Insurance Co.

Factory Mutual Insurance Co. grew its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 11.9% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 665,300 shares of the biopharmaceutical company’s stock after buying an additional 70,900 shares during the quarter. Factory Mutual Insurance Co. owned 0.30% of Alexion Pharmaceuticals worth $92,483,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Brown Advisory Inc. raised its holdings in shares of Alexion Pharmaceuticals by 297.9% in the 2nd quarter. Brown Advisory Inc. now owns 20,261 shares of the biopharmaceutical company’s stock worth $2,516,000 after purchasing an additional 15,169 shares during the period. Essex Financial Services Inc. bought a new stake in shares of Alexion Pharmaceuticals in the 2nd quarter worth approximately $232,000. Tyers Asset Management LLC raised its holdings in shares of Alexion Pharmaceuticals by 15.5% in the 2nd quarter. Tyers Asset Management LLC now owns 6,050 shares of the biopharmaceutical company’s stock worth $751,000 after purchasing an additional 814 shares during the period. CIBC Asset Management Inc raised its holdings in shares of Alexion Pharmaceuticals by 2.0% in the 2nd quarter. CIBC Asset Management Inc now owns 55,003 shares of the biopharmaceutical company’s stock worth $6,829,000 after purchasing an additional 1,091 shares during the period. Finally, Salem Investment Counselors Inc. raised its holdings in shares of Alexion Pharmaceuticals by 2.8% in the 2nd quarter. Salem Investment Counselors Inc. now owns 32,810 shares of the biopharmaceutical company’s stock worth $4,073,000 after purchasing an additional 905 shares during the period. 93.06% of the stock is currently owned by hedge funds and other institutional investors.

A number of research firms recently commented on ALXN. ValuEngine raised shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, July 12th. BidaskClub cut shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. Evercore ISI reaffirmed an “outperform” rating and issued a $158.00 price target on shares of Alexion Pharmaceuticals in a report on Thursday, July 26th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $123.00 price target on shares of Alexion Pharmaceuticals in a report on Friday, July 27th. Finally, Stifel Nicolaus cut shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating and lowered their price target for the stock from $154.00 to $130.00 in a report on Tuesday, August 7th. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $160.32.

Alexion Pharmaceuticals stock opened at $130.58 on Wednesday. Alexion Pharmaceuticals, Inc. has a 1-year low of $102.10 and a 1-year high of $144.91. The company has a market capitalization of $30.98 billion, a P/E ratio of 25.31, a price-to-earnings-growth ratio of 1.27 and a beta of 0.79. The company has a quick ratio of 2.27, a current ratio of 2.72 and a debt-to-equity ratio of 0.33.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Thursday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.58. Alexion Pharmaceuticals had a negative net margin of 2.68% and a positive return on equity of 15.21%. The business had revenue of $1.05 billion during the quarter, compared to analyst estimates of $976.81 million. During the same period in the previous year, the business earned $1.56 EPS. Alexion Pharmaceuticals’s revenue was up 14.5% compared to the same quarter last year. Sell-side analysts forecast that Alexion Pharmaceuticals, Inc. will post 6.45 EPS for the current year.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Recommended Story: How can investors find ex-dividend dates?

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Related posts

Leave a Comment